Pure Global

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression - Trial NCT06419608

Access comprehensive clinical trial information for NCT06419608 through Pure Global AI's free database. This Phase 2 trial is sponsored by Biohaven Therapeutics Ltd. and is currently Not yet recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06419608
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06419608
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder

Study Focus

Major Depressive Disorder

BHV-7000

Interventional

drug

Sponsor & Location

Biohaven Therapeutics Ltd.

Biohaven Pharmaceuticals, Inc.

Timeline & Enrollment

Phase 2

Jun 01, 2024

Jul 01, 2025

300 participants

Primary Outcome

Change in Montgomery- Åsberg Depression Rating Scale (MADRS) total score from baseline to week 6

Summary

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants
 with Major Depressive Disorder (MDD)

ICD-10 Classifications

Recurrent depressive disorder
Recurrent depressive disorder, unspecified
Depressive conduct disorder
Other recurrent depressive disorders
Recurrent depressive disorder, current episode moderate

Data Source

ClinicalTrials.gov

NCT06419608

Non-Device Trial